Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Shares of Global Blood Therapeutics (GBT) are skyrocketing today, up by 36.6% as of 1:27 p.m. ET. The biotech's stock is roaring higher in the wake of a report from Bloomberg News that the company ...

Over 12 months, Global Blood Therapeutics reported revenue of US$165m, which is a gain of 245%, although it did not report any earnings before interest and tax.

So what Global Blood Therapeutics said it is selling 5.1 million shares of common stock to the public for $24.50 per share. That should net the company $125 million after deducting fees. The ...

Global Blood Therapeutics revealed that there were around 925 new prescriptions for Oxbryta during Q2. In addition, the company revealed that they have seen a substantial number of patients that ...

Global Blood Therapeutics provided investors with a preliminary update from its phase 3 HOPE study. This 154-patient trial is testing its drug Voxelotor as a treatment for kids with sickle cell ...

Global Blood Therapeutics novel sickle cell disease drug, Oxbryta, continues to outperform revenue expectations early in its launch despite the "pandemic era". It is evident in both the data and ...

SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of preliminary results from the single-dose ...

Sickle cell disease is a genetic blood disorder that affects about 70,000 to 100,000 people in the U.S. Oxbryta generated $55.2 million in sales for Global Blood Therapeutics in the first quarter.

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of a case study in which a patient with sickle ...

So what Global Blood Therapeutics has just one drug in its clinical-stage pipeline: voxelotor, an oral, once-daily treatment for sickle cell disease (SCD). Voxelotor helps prevent red blood cells ...

Shares of rare-disease specialist Global Blood Therapeutics (GBT) are rising sharply for the second day in a row. As of 12:38 p.m. ET, the drugmaker's stock was up by a healthy 38.4%.